Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype

Gastroenterology

Volumn 142, Issue 5, 2012, Pages

  McGilvray, Ian ^b,c   Feld, Jordan J ^a,c   Chen, Limin ^c   Pattullo, Venessa ^d   Guindi, Maha ^c,e   Fischer, Sandra ^b,c   Borozan, Ivan ^c   Xie, Gang ^f   Selzner, Nazia ^b,c   Heathcote, E Jenny ^a,c   Siminovitch, Katherine ^c,f  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d University of Sydney   (Australia)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Liver Disease; Prognostic Factor; SVR; Treatment Outcome

Indexed keywords

INTERFERON STIMULATED PROTEIN; INTERLEUKIN 28B; MESSENGER RNA; MYXOVIRUS A PROTEIN 1; MYXOVIRUS RESISTANCE PROTEIN A; NUCLEIC ACID BINDING PROTEIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; UNCLASSIFIED DRUG;

ARTICLE; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84862777615     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2012.01.028     Document Type: Article

References (24)

1. M.W. Fried, M.L. Shiffman, K.R. Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
2. M.P. Manns, J.G. McHutchison, S.C. Gordon Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
3. P.Y. Kwo, E.J. Lawitz, J. McCone Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
4. J.G. McHutchison, G.T. Everson, S.C. Gordon Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
5. J.M. Pawlotsky The results of phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending Gastroenterology 140 2011 746 754
6. B.R. Bacon, S.C. Gordon, E. Lawitz Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
7. A. Kau, J. Vermehren, C. Sarrazin Treatment predictors of a sustained virologic response in hepatitis B and C J Hepatol 49 2008 634 651
8. L. Chen, I. Borozan, J. Feld Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection Gastroenterology 128 2005 1437 1444
9. J.J. Feld, S. Nanda, Y. Huang Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response Hepatology 46 2007 1548 1563
10. T. Asselah, I. Bieche, I. Laurendeau Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C Gastroenterology 129 2005 2064 2075
11. M. Sarasin-Filipowicz, E.J. Oakeley, F.H. Duong Interferon signaling and treatment outcome in chronic hepatitis C Proc Natl Acad Sci U S A 105 2008 7034 7039
12. L. Chen, I. Borozan, J. Sun Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection Gastroenterology 138 2010 1123 1133 e1-3
13. D. Ge, J. Fellay, A.J. Thompson Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
14. A.J. Thompson, A.J. Muir, M.S. Sulkowski Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus Gastroenterology 139 2010 120 129 e18
15. V. Suppiah, M. Moldovan, G. Ahlenstiel IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 2009 1100 1104
16. D.L. Thomas, C.L. Thio, M.P. Martin Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
17. A. Balagopal, D.L. Thomas, C.L. Thio IL28B and the control of hepatitis C virus infection Gastroenterology 139 2010 1865 1876
18. M. Honda, A. Sakai, T. Yamashita Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C Gastroenterology 139 2010 499 509
19. M.T. Dill, F.H. Duong, J.E. Vogt Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C Gastroenterology 140 2011 1021 1031 e10
20. J.H. Hoofnagle, L.B. Seeff Peginterferon and ribavirin for chronic hepatitis C N Engl J Med 355 2006 2444 2451
21. H. Akaike A new look at the statistical model identification IEEE Trans Autom Control 19 1974 716 723
22. M.W. Browne Cross-validation methods J Math Psychol 44 2000 108 132
23. M. Frese, T. Pietschmann, D. Moradpour Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway J Gen Virol 82 2001 723 733
24. F. Poordad, J. McCone Jr, B.R. Bacon Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206